



CDPHP® Medicare Advantage 2023 Part B versus Part D Determinations

Drugs are subject to a Part B vs. D Determination for All Part D Members

ABELCET INJ
ABRAXANE INJ
acetylcysteine nebulizer solution
acyclovir sodium iv soln
AKYNZEO CAPS
albuterol sulfate nebulizer solution
ALIMTA INJ
AMINO ACID 10% SOLUTION
AMINOSYN 10% SOLUTION
AMINOSYN II INJ 10%
AMINOSYN PF INJ 7%
amphotericin inj
aprepitant caps, pak
azacitidine inj
azathioprine tab
BENDEKA INJ
budesonide inhalation suspension
calcitonin nasal spray
*calcitriol**
carboplatin inj
*cinacalcet tabs**
cisplatin inj
CLINMIX INJ 6/5, 8/10, 8/14
CLINIMIX INJ 4.25/D10
CLINIMIX INJ 4.25/D5W
CLINIMIX INJ 5%/D15W
CLINIMIX INJ 5%/D20W
CLINISOL SF INJ 15%
CLINOLIPID EMULSION 20%
cromolyn sodium nebulizer solution
cyclophosphamide cap, inj, tabs
cyclosporine
cyclosporine modified
cytarabine inj
DEXTROSE INJ 50%, 70%
DOCETAXEL INJ
doxorubicin inj
dronabinol caps 2.5mg, 5mg, 10mg

(continued on next page)

*These drugs are subject to a Part B vs. D determination for Part D members with End Stage Renal Disease. Requests for a Part B versus Part D determination should be directed to the CDPHP pharmacy department at (518) 641-3784 or 1-800-274-2332, or faxed to (518) 641-3208.

CDPHP® Medicare Advantage 2023 Part B versus Part D Determinations

(continued from previous page)

EMEND SUSPENSION

ENGERIX-B INJ

epirubicin inj

etoposide inj

everolimus tabs

fluorouracil inj

FREAMINE III INJ 10%

fulvestrant injection 250mg/ml

ganciclovir inj

gemcitabine inj

GENGRAF

granisetron tab

*heparin sodium injection 1000u/ml, 5000u/ml, 10000u/ml, 20000u/ml**

HUMULIN R U-500 INSULIN

*ibandronate 150mg tabs**

IMMUNE GLOBULIN

IMOVAX RABIES INJ

INTRALIPID INJ 20%, 30%

INTRON A 6mu, 10mu, 18mu, 50mu

ipratropium/albuterol nebulizer solution

ipratropium bromide 0.02% inhalation solution

irinotecan inj

KADCYLA INJ

leucovorin calcium inj

levalbuterol nebulization solution

*levocarnitine 1gm/10ml oral soln, and 330mg tab**

*lidocaine injection 0.5%, 1%, 1.5%, 2%**

*lidocaine/prilocaine topical cream**

morphine sulfate iv soln PF 2mg/ml, 4mg/ml, 5mg/ml, 8mg/ml, 10mg/ml

morphine sulfate iv soln 1 mg/ml, 4mg/ml, 8mg/ml, 10mg/ml

mycophenolate mofetil

mycophenolic tab 180mg, 360mg

NEORAL

NULOJIX INJ

nutrilipid emulsion 20%

ondansetron tabs, oral solution, oral dissolving tabs

oxaliplatin inj

paclitaxel inj

*pamidronate injection**

paraplatin inj

paricalcitol

pemetrexed iv soln

(continued on next page)

*These drugs are subject to a Part B vs. D determination for Part D members with End Stage Renal Disease. Requests for a Part B versus Part D determination should be directed to the CDPHP pharmacy department at (518) 641-3784 or 1-800-274-2332, or faxed to (518) 641-3208.

CDPHP® Medicare Advantage 2023 Part B versus Part D Determinations

(continued from previous page)

pentamidine inhalation

PLENAMINE INJ 15%

PREHEVBRIO SUSP 10MCG/ML

PREMASOL SOLUTION 10%

PROCALAMINE INJ 3%

PROGRAF

PROSOL INJ 20%

PULMOZYME inhalation solution

RABAVERT INJ

RAPAMUNE

RECOMBIVAX HB 5MCG/0.5ML, 10MCG/ML, 40MCG/ML

SANDIMMUNE

sirolimus tabs, solution

SYNTHAMIN 17 10% SOLUTION

tacrolimus caps

tobramycin nebulizer solution 300mg/5ml

toposar inj

tpn electrol inj

TRAVASOL INJ 10%

treprostinil injection 1mg/ml, 2.5mg/ml, 5mg/ml, 10mg/ml

TROPHAMINE INJ 10%

VARUBI TABS

vincristine inj

vinorelbine inj

zoledronic acid injection 4mg/5ml, 4mg/100ml, 5mg/100ml

ZORTRESS

*These drugs are subject to a Part B vs. D determination for Part D members with End Stage Renal Disease. Requests for a Part B versus Part D determination should be directed to the CDPHP pharmacy department at (518) 641-3784 or 1-800-274-2332, or faxed to (518) 641-3208.